Literature DB >> 15640502

The role of radiotherapy for thymic carcinoma.

Tetsuo Nonaka1, Yoshio Tamaki, Keiko Higuchi, Hiroyuki Katoh, Masumi Nakahashi, Hiroyuki Horikoshi, Kenro Takahashi, Koichi Minato, Shiro Sugihara, Masaru Kojima.   

Abstract

OBJECTIVE: The aim of this study is to evaluate retrospectively the role of radiotherapy for thymic carcinoma.
METHODS: Between 1973 and 1998, 14 patients with thymic carcinoma were treated at Gunma Prefectural Cancer Center. Two patients who had hematogenous metastasis were excluded from this study, therefore 12 patients were analyzed. The Masaoka staging system was used; four patients were diagnosed with stage III disease and eight patients with stage IV disease. The pathological subtype according to the World Health Organization histological criteria for thymic tumors was squamous cell carcinoma (low-grade histology) in six cases and undifferentiated carcinoma (high-grade histology) in six. Ten patients underwent thoracotomy, and two patients underwent excisional biopsy without thoracotomy. Ten patients (83%) received radiotherapy as a curative intent, and the median dose was 60 Gy. Systemic chemotherapy was administered to four patients (33%), and the majority (75%) of the regimens contained cisplatin.
RESULTS: The 3-year overall survival rate was 25%. Histological subtype (low-grade versus high-grade), surgical resection (complete versus incomplete), radiotherapy and chemotherapy were evaluated as prognostic factors in a univariate analysis. Low-grade histology and complete resection were good prognostic factors, although these were not statistically significant. Patients who received radiotherapy had a better outcome than those who did not. The major sites of recurrence were the pleura and pericardium. Recurrence within the radiation field was observed in one of seven patients in whom failure patterns could be evaluated.
CONCLUSION: Complete resection is mandatory if possible. Radiotherapy plays an important role in treating thymic carcinoma in terms of reducing local recurrence and prolonging survival time. Establishment of an innovative treatment protocol that includes chemotherapy is necessary to control intrathoracic relapse and distant metastasis.

Entities:  

Mesh:

Year:  2004        PMID: 15640502     DOI: 10.1093/jjco/hyh141

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  13 in total

1.  Reconstruction of mediastinal vessels for invasive thymoma: a retrospective analysis of 25 cases.

Authors:  Yifeng Sun; Chang Gu; Jianxin Shi; Wentao Fang; Qingquan Luo; Dingzhong Hu; Shijie Fu; Xufeng Pan; Yong Chen; Yu Yang; Haitang Yang; Heng Zhao; Haiquan Chen
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

2.  Stereotactic ablative radiotherapy with CyberKnife for advanced thymic carcinoma: a case report.

Authors:  C Y Fan; W Y Huang; Y M Jen; M J Lin; K T Lin
Journal:  Curr Oncol       Date:  2015-10       Impact factor: 3.677

Review 3.  Radiotherapy for thymic neoplasms.

Authors:  Clifton D Fuller; Emma H Ramahi; Noel Aherne; Tony Y Eng; Charles R Thomas
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

4.  Early-stage thymic carcinoma: is adjuvant therapy required?

Authors:  Mitsuaki Sakai; Takuya Onuki; Masaharu Inagaki; Masatoshi Yamaoka; Shinsuke Kitazawa; Keisuke Kobayashi; Kesato Iguchi; Shinji Kikuchi; Yukinobu Goto; Masataka Onizuka; Yukio Sato
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895

5.  Intrapericardial primary thymic carcinoma in a 73-year-old man.

Authors:  Ana Maria Calderon; Juan Andres Merchan; Juan Carlos Rozo; Cesar Ivan Guerrero; Bernardo Treistman; Laura E Sulak; Benjamin Y C Cheong; German Rodríguez; Andrés Mesa
Journal:  Tex Heart Inst J       Date:  2008

6.  Adjuvant therapy in stage II thymic carcinoma.

Authors:  Zhengbo Song; Yiping Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-04       Impact factor: 4.553

Review 7.  Radiotherapy for thymic carcinoma: adjuvant, inductive, and definitive.

Authors:  Ritsuko Komaki; Daniel R Gomez
Journal:  Front Oncol       Date:  2014-01-10       Impact factor: 6.244

8.  Long-term follow-up and prognostic factors for advanced thymic carcinoma.

Authors:  Jun-xin Wu; Hui-qin Chen; Ling-dong Shao; Su-fang Qiu; Qian-yu Ni; Bu-hong Zheng; Jie-zhong Wang; Jian-ji Pan; Jin-luan Li
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

9.  Chemoradiotherapy for unresectable cases of thymic epithelial tumors: a retrospective study.

Authors:  Jumpei Kashima; Yusuke Okuma; Hiroto Murata; Kageaki Watanabe; Yukio Hosomi; Tsunekazu Hishima
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

Review 10.  Chemotherapy for thymic carcinoma and advanced thymoma in adults.

Authors:  Mao Ling Wei; Deying Kang; Lijia Gu; Meng Qiu; Liao Zhengyin; Yanming Mu
Journal:  Cochrane Database Syst Rev       Date:  2013-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.